The startup develops exosome-based diagnostics that utilize liquid biopsies to detect early-stage cancer and monitor tumor responses to treatment. By identifying unique protein biomarkers from extracellular vesicles, the technology provides over 90% accuracy in cancer detection while eliminating the need for invasive tissue biopsies.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for cancer detection often rely on invasive tissue biopsies, which can be risky, painful, and costly for patients. Early-stage cancer detection is critical for improving treatment outcomes, but current liquid biopsy technologies lack the accuracy needed for reliable early diagnosis.
Solution
Nexosome Oncology is developing exosome-based diagnostics utilizing liquid biopsies to detect early-stage cancer and monitor treatment response. The company's technology isolates extracellular vesicles (EVs) from plasma and identifies unique protein biomarkers expressed on these EVs that reflect tumor biology. By focusing on EV plasma subfractions, Nexosome's approach yields differentially expressed biomarkers, providing a unique view of tumor biology and patient response. These biomarkers are then translated into rapid, inexpensive, and facile ELISA assays using mass spectrometry and machine learning workflows to define multiplexes. The assays demonstrate high accuracy in multiple cancer indications, potentially eliminating the need for invasive tissue biopsies.
Target Audience
The primary target audience includes diagnostics companies and pharmaceutical companies focused on early detection, recurrence monitoring, and cancer staging, as well as academic researchers interested in longitudinal sample analysis.
Features
- Proprietary EV isolation techniques for liquid biopsies
- Deep proteomic biomarker discovery using mass spectrometry
- Machine learning-driven proteomic biomarker discovery pipeline
- Rapid translation of biomarker multiplexes into clinical ELISA assays
- High accuracy and reproducibility in early cancer detection
- Ability to identify approximately 2,000 proteins from EV preparations